Meeting Vaccine Demand: Workforce Solutions for the 2026–2027 Flu Cycle

Flu season comes every year. But that doesn’t make preparation predictable.

Life sciences organizations have a relatively small window to develop, test, and distribute updated seasonal vaccines before cases begin climbing. And while the deadline stays relatively fixed, the virus—and the workforce needed to respond to it—keeps changing.

The 2026–2027 flu cycle is a good example. Interim data from the Centers for Disease Control and Prevention (CDC) showed that the 2025–2026 influenza vaccine continued to provide protection against influenza-related outpatient visits and hospitalizations, with effectiveness varying by age group. Estimates ranged from 38%–41% against outpatient visits among children and adolescents and 22%–34% among adults, while effectiveness against hospitalization was 41% and 30%, respectively.

Now, the industry is preparing for another shift. For the upcoming 2026–2027 season, the U.S. Food and Drug Administration (FDA) has recommended changes to all three virus components included in trivalent seasonal influenza vaccines compared with the previous season.

Meanwhile, clinical trials continue evaluating new formulations and technologies, including mRNA-based vaccines designed to provide broader, longer-lasting protection. But innovation still has to fit within the realities of flu season.

Seasonal vaccine programs operate within a narrow window. Organizations need enough time to ramp up clinical sites, enroll participants, collect real-world data, and move trials forward while the virus is actively circulating.

For life sciences organizations, the challenge is twofold: How do you get the right people in place quickly, and how do you keep them engaged without building a year-round workforce for a seasonal need?

Solving the Seasonal Staffing Squeeze

Seasonal clinical trial staffing requires a careful balance between workforce readiness and cost.

Organizations need talent in place early enough to prepare for peak trial activity. But hiring full-time employees for a short-term surge can be costly, while contract talent comes with its own balancing act: getting the timing and scheduling right.

The early weeks of a seasonal protocol illustrate the challenge. If contractors receive limited or fluctuating hours before trial volume ramps up, they may leave for opportunities that offer more predictable schedules. Over-schedule too early to keep that talent engaged, and the organization may end up paying for capacity it doesn’t yet need.

Then, once flu activity and trial enrollment accelerate, the equation changes again. Clinical sites may need to add capacity quickly, shift specialized talent between locations, or find professionals with very specific clinical skills—all within a timeline that isn’t especially forgiving.

The goal, then, isn’t simply adding more people. It’s building enough flexibility into the workforce model to scale talent alongside trial demand.

For the 2026–2027 flu cycle, that can include:

• Strategic Capacity Scaling: Build structured contractor ramp-up timelines that help retain talent early in the season while aligning staffing levels with anticipated trial volume.
• Clinical Cross-Training: Expand the available talent pool by deploying Certified Medical Assistants (CMAs) and other qualified clinical professionals with relevant skills, such as respiratory specimen collection and phlebotomy, where protocol requirements allow.
• Cross-Site Resource Flexing: Shift specialized personnel across geographic testing locations as enrollment and trial volumes fluctuate.

Turn Vaccine Innovation Into Compliant Impact

Behind every vaccine breakthrough, quality milestone, and successful strain update are the people working tirelessly to protect global health.

For seasonal vaccine programs, those people need to be in the right place at the right time. Compressed trial and production windows can quickly magnify an unfilled role, a skills gap, or a staffing model that can’t adjust alongside demand.

As Dean Lothrop, Vice President of Clinical Research at Medix, explains:

“When it comes to flu vaccine rollouts, our clients tell us they can’t afford a single day of downtime. We often begin conversations about needs in mid-to-late summer for logistics and distribution staffing. Then, for clinical sites, we see the surge just weeks before the virus circulates to capture vital, real-world data with the vaccine administration.”

Whether your pipeline demands phlebotomy-ready clinical support, high-throughput lab technicians, or specialized regulatory experts, having the right talent in place can help keep timelines moving, support compliance, and meet the demands of the 2026–2027 flu cycle head-on.

Roles Most In-Demand During Flu Season Trials

The workforce surge doesn’t stop at the clinical site. Seasonal vaccine programs can create demand across clinical operations, laboratories, data management, regulatory affairs, and quality.

Here are some of the roles we most commonly see life sciences organizations ramp up during flu season trials:

Clinical Research and Site Operations

• Clinical Research Coordinators (CRCs): Oversee day-to-day site operations, protocol fidelity, and complex patient data tracking.
• Certified Medical Assistants (CMAs) and Research Assistants: Provide patient-facing support, assist with appropriate screening activities, and perform basic electronic medical record (EMR) tracking to free up senior CRC capacity.
• Phlebotomists: Support blood-draw sub-protocols used to track antibody responses.
• Registered Nurses (RNs) and Licensed Practical Nurses (LPNs): Administer investigational vaccine doses, monitor patients after injection for adverse events, and collect respiratory specimens
• Clinical Data Entry Specialists: Accurately enter high volumes of rapid-enrollment data into electronic data capture (EDC) systems.

Laboratory, Research, and Development

• Laboratory Technicians and Assistants: Manage high volumes of respiratory swabs and serum samples while maintaining sample chain of custody.
• Research Associates in Virology and Immunology: Run assays such as enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and hemagglutination inhibition testing to evaluate vaccine potency, efficacy, and immune response.
• Biochemists and Molecular Biologists: Support optimization of antigen formulations for seasonal and emerging vaccine platforms.

Clinical Data Management and Biostatistics

• Clinical Data Managers (CDMs): Design, build, and validate databases for rapid-start protocols while supporting clean data capture.
• Biostatisticians: Analyze complex datasets to evaluate safety baselines, efficacy endpoints, and antibody responses across patient cohorts.
• Clinical Database Programmers: Build and integrate EMR and EDC systems to help prevent data bottlenecks during high-volume periods.

Regulatory Affairs and Drug Safety

• Pharmacovigilance (PV) Specialists and Case Processors: Monitor, evaluate, and document adverse events reported during the trial.
• Regulatory Affairs Specialists: Support protocol amendments, Investigational New Drug (IND) updates, and seasonal strain variation filings with regulatory agencies such as the FDA.
• Medical Writers: Develop clinical study reports (CSRs), protocols, informed consent documents, and other required documentation on compressed timelines.
• Trial Management and Quality Assurance
• Clinical Research Associates (CRAs) and Monitors: Conduct site monitoring visits or remote source data verification to help maintain compliance across high-volume sites.
• Clinical Project Managers (CPMs): Oversee trial milestones, manage vendor relationships, and coordinate logistics between clinical sites and central laboratories.
• Quality Assurance (QA) Auditors: Conduct protocol-specific audits to support Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) compliance during peak production and testing periods.

Preparing Your Workforce for the 2026–2027 Flu Cycle

Navigating the clinical tightrope of the seasonal flu cycle calls for operational flexibility. As the industry responds to updated trivalent strains and emerging mRNA platforms, workforce models need to keep pace with rapidly changing trial demands.

Life sciences leaders who implement strategic scaling, cross-train adaptable clinical personnel, and embrace flexible talent solutions can better protect their timelines and operational stability. Having the right workforce strategy in place before demand peaks can help teams stay focused on what matters most: keeping critical vaccine programs moving forward.

Medix partners with life sciences organizations to build specialized teams across clinical operations, laboratory functions, data management, regulatory affairs, and quality, with workforce solutions designed to scale alongside changing trial demands.

Preparing for the 2026–2027 seasonal vaccine surge? Connect with Medix to build a workforce strategy around your timeline, protocol needs, and operational goals.